000 01607 a2200385 4500
005 20250516004412.0
264 0 _c20110211
008 201102s 0 0 eng d
022 _a1549-490X
024 7 _a10.1634/theoncologist.2009-0331
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHolloway, Robert W
245 0 0 _aTolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
_h[electronic resource]
260 _bThe oncologist
_c2010
300 _a1073-82 p.
_bdigital
500 _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xadverse effects
650 0 4 _aCarboplatin
_xadministration & dosage
650 0 4 _aDeoxycytidine
_xadministration & dosage
650 0 4 _aDisease-Free Survival
650 0 4 _aDoxorubicin
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Recurrence, Local
_xdrug therapy
650 0 4 _aOvarian Neoplasms
_xdrug therapy
650 0 4 _aPolyethylene Glycols
_xadministration & dosage
650 0 4 _aGemcitabine
700 1 _aGrendys, Edward C
700 1 _aLefebvre, Patrick
700 1 _aVekeman, Francis
700 1 _aMcMeekin, Scott
773 0 _tThe oncologist
_gvol. 15
_gno. 10
_gp. 1073-82
856 4 0 _uhttps://doi.org/10.1634/theoncologist.2009-0331
_zAvailable from publisher's website
999 _c20234763
_d20234763